Brilliant Violet 421™ anti-human CD141 (Thro
- 产品名称：
- Brilliant Violet 421™ anti-human CD141 (Thro
- 产品类别：
- 抗体
- 产品编号：
- 344113
- 产品应用：
- 344113
[价格]
| 规格 |
价格 |
库存 |
| 25tests |
￥ 2316 |
1 |
- Verified Reactivity
- Human
- Reported Reactivity
- African Green, Baboon
- Antibody Type
- Monoclonal
- Host Species
- Mouse
- Formulation
- Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
- Preparation
- The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 421? under optimal conditions.
- Concentration
- Lot-specific (to obtain lot-specific concentration, please enter the lot number in our Concentration and Expiration Lookup or Certificate of Analysis online tools.)
- Storage & Handling
- The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
- Application
-
FC - Quality tested
- Recommended Usage
Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 ?l per million cells in 100 ?l staining volume or 5 ?l per 100 ?l of whole blood.
Brilliant Violet 421? excites at 405 nm and emits at 421 nm. The standard bandpass filter 450/50 nm is recommended for detection. Brilliant Violet 421? is a trademark of Sirigen Group Ltd.
Learn more about Brilliant Violet?.
This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents. - Excitation Laser
- Violet Laser (405 nm)
- Product Citations
-
- Mulder K, et al. 2021. Immunity. 54(8):1883-1900.e5. PubMed
- Zaal A et al. 2017. Frontiers in immunology. 0.901388889 . PubMed
- Jordan S, et al. 2020. Cell. 178(5):1102-1114.e17.. PubMed
- Motwani MP, et al. 2018. JCI Insight. 3:e94463. PubMed
- Molina MS, et al. 2021. Front Immunol. 12:699128. PubMed
- RRID
- AB_2562956 (BioLegend Cat. No. 344113) AB_2563858 (BioLegend Cat. No. 344114)
- Structure
- Single chain, type I membrane glycoprotein, 75 kD
- Distribution
-
Macrophages, monocytes, subset of myeloid dendritic cells, vascular endothelial cells, keratinocytes
- Function
- After thrombin binding, CD141 activates protein C, which degrades clotting factors Va and VIIIa and reduces the amount of thrombin generated.
- Interaction
- Protein C, Thrombin-activatable fibrinolysis inhibitor (TAFI), Platelet factor 4 (PF4)
- Ligand/Receptor
- Thrombin
- Cell Type
- Dendritic cells, Endothelial cells, Macrophages, Monocytes
- Biology Area
- Immunology, Innate Immunity
- Molecular Family
- CD Molecules
- Antigen References
-
1. Suzuki K, et al. 1987. EMBO J. 6:1891.
2. Esmon CT, et al. 1989. J. Biol. Chem. 264:4743.
3. Delvaeye M, et al. 2009. N. Engl. J. Med. 361:345.
4. Shi CS, et al. 2008. Blood 112:3661.
5. Chen LC, et al. 2009. J. Infect. 58:368.
- Gene ID
- 7056 View all products for this Gene ID
- UniProt
- View information about CD141 on UniProt.org
